Table 1 Cyberknife®-SBRT: clinical characteristics of 100 patients
T Stage | Patients |
|---|---|
T1c | 44 (44%) |
T2a-b | 29 (29%) |
(T2a, 10 pts) | |
(T2b, 19 pts) | |
T2c | 27 (27%) |
Gleason score | |
<6 (2+2, 2+3, 3+2) | 8 (8%) |
6 (3+3) | 76 (76%) |
>7 (3+4 11 pts, 4+3 4 pts, 5+5 1 pt) | 16 (16%) |
PSA | |
at diagnosis | ng/ml |
All patients | 7.72 ng/ml |
SBRT (71 pts) | 6.48 ng/ml |
SBRT+ADT (29 pts) | 10.77 ng/ml |
Pre-treatment | ng/ml |
All patients | 5.03 ng/ml |
SBRT (71 pts) | 6.31 ng/ml |
SBRT+ADT (29 pts) | 1.90 ng/ml |
Risk category | Patients |
Low (PSA <10, GS 6, T1c, T2a) | 41 (41%) |
Intermediate (PSA >10, GS 7 or T2b-c) | 42 (42%) |
High (PSA >20, GS 8–10, 2 Int. risk features) | 17 (17%) |
Prostate volume ( medium 33 cc.) | |
≤ 33 cc. | 51 (51%) |
> 33 cc. | 49 (49%) |
TURP before SBRT (1–16 years) | 7 (7%) |
ADT | |
Before SBRT (median 6 months) | 8 (27%) |
Concomitant and after SBRT (median 12 months) | 21 (73%) |